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The promising potential of bioorthogonal catalysis in biomedicine is inspiring incremental 
efforts to design strategies that regulate drug activity in living systems. To achieve this, it is not 
only essential to develop customized inactive prodrugs and biocompatible metal catalysts, but 
also the right physical environment for them to interact and enable drug production under spatial 
and/or temporal control. Towards this goal, here we report the first inactive precursor of the 
potent broad-spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable in cell culture and 
labile to Pd catalysts. This new prodrug is effectively uncaged in cancer cell culture by Pd 
nanosheets captured within agarose and alginate hydrogels, providing a biodegradable catalytic 
framework to achieve controlled release of one of the most important chemotherapy drugs in 
medical practice. The compatibility of bioorthogonal catalysis and physical hydrogels opens up 





Despite the growing impact of molecularly-targeted therapies in cancer, chemotherapy still 
stands as the main pharmaco-therapeutic choice to treat most kinds of solid malignancies.1-3 The 
third-generation cytotoxic drug paclitaxel (PTX) is one of the most widely used 
chemotherapeutics4,5 and the anticancer drug currently enrolled in more active clinical trials 
(>1,100)6. First isolated from the bark of the Pacific yew tree, the initiation of PTX’s phase 2 
trials in the 80s raised ecological concerns over the impact on yew populations and sparked the 
renowned race to complete its total synthesis.5,7 Nowadays, PTX is produced by a semi-synthetic 
protocol from sustainable sources7,8 and globally used ―alone or in combination― in the 
treatment of many of the most prevalent types of cancer, including breast, ovarian and lung 
cancer.4,5 There are, however, important dose-limiting adverse effects associated to PTX therapy 
(myelosuppression, peripheral neuropathy, cardiac toxicity) that restrains its systemic anticancer 
efficacy. For that reason, over the last decades much research on PTX has been steered to 
develop efficient drug delivery systems that improve its clinical tolerability8,9 and low toxicity 
prodrugs.10,11 Innovative methods to localize drug activity at the tumor site are still essential to 
maximize the clinical potential of PTX, not least because its ever-growing role in chemotherapy 
regimens.  
The catalytic scope of some of the transition metals most commonly used in chemistry labs has 
recently expanded from round-bottomed flasks to cell culture plates and animals. Ruthenium,12-17 
palladium,15-31 gold,32-34 copper35,36 or iron-based37,38 catalysts have demonstrated their 
compatibility with saline aqueous solutions and their capacity to mediate chemo-specific 
processes in complex biological systems. The emerging field of bioorthogonal catalysis has 
enriched the wealth of methods available to label biomolecules,20,21 release cytotoxic 
drugs14,17,24,26,38 or modulate biological functions.15,16,23,31 In this context, our lab has contributed 
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to the use of palladium (Pd) as a heterogeneous catalytic system to generate clinically-approved 
anticancer drugs in living environs.24,25,39-43 Such an approach aims to achieve increased control 
over when and where prodrugs are converted into active drugs by exploiting activation strategies 
that do not rely on metabolic reactions.44,45 Up to now, non-degradable materials have been used 
to capture Pd nanoparticles and protect them from the biological milieu, meaning that the devices 
will stay at the affected tissue even after completing their catalytic function.41 This situation is 
certainly useful for cancers that tend to relapse at the same location, but not quite as much for 
short-lived neoadjuvant therapies or patients with multiple tumor foci. Hence, it would also be 
desirable to develop implantable systems that securely host Pd nanoparticles to induce local 
prodrug activation for a limited period of time and, afterwards, degrade and naturally eliminate 
from the organism.  
Here we report the development of a novel PTX precursor that exhibits up to 700-fold lower 
activity than the parent drug and incorporates a Pd-sensitive masking group (Scheme 1). In the 
presence of Pd catalysts, a rapid depropargylation reaction takes place to trigger the release of 
PTX. In addition, we report the first investigation on the use of physical hydrogels to capture Pd 
catalysts and their capacity to carry out bioorthogonal uncaging reactions under physiological 
conditions.    
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Scheme 1. Proposed Pd-mediated activation strategy in cell culture (left) and synthesis of Pro-PTX 
(right). Cell culture: Pd-mediated O-depropargylation of Pro-PTX is thermodynamically favored by the 
generation of CO2 and designed to trigger an intramolecular cyclization event that releases PTX and 1,3-
dimethyl-2-imidazolidinone. Dealkylation step in water is expected to afford nontoxic 1-
hydroxyacetone.24 Reaction byproducts could not be confirmed by LCMS. Chemistry lab: Carbamate-
protected Pro-PTX is semi-synthetically prepared from PTX in two steps by successive reactions with p-
nitrophenyl chloroformate and N-(propargyloxycarbonyl)-N,N’-dimethylethylenediamine, 4. 
Results and discussion 
Design and synthesis of a biochemically stable Pd-sensitive prodrug of PTX. The structure-
activity relationships of PTX and its analogues have been the subject of intensive research.46,10 It 
is well established that one of the essential groups for their bioactivity is the secondary alcohol at 
the C2’ position of the side chain. Masking of this aliphatic OH with various chemical groups 
(carbonates, esters, carbamates, etc.) has been used to develop PTX prodrugs for different 
purposes.47,10 In light of previous studies25 showing that carbamate-based masking groups exhibit 
significantly higher stability in cell culture than carbonate ones and the need to generate a 
prodrug that endure the cell metabolism, a bis-carbamate group connected through a N,N’-
dimethylethylenediamine spacer48 was used to mask the C2’-OH of PTX (Scheme 1). To provide 
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sensitivity to Pd catalysis, an O-propargyl moiety was incorporated at the terminal carbamate 
that, after cleavage, triggers a self-immolative cascade resulting in the release of PTX.  
Pro-PTX was prepared following the semi-synthetic route described in Scheme 1 (see the 
synthetic procedure in the Experimental Section and NMR spectra in the Supp. Inf.). PTX was 
reacted with p-nitrophenyl chloroformate in the presence of pyridine to incorporate a reactive 
carbonate group at its C2’-OH position. Reaction of N-Boc-protected ethylenediamine 2 with 
propargyl chloroformate followed by Boc deprotection under acidic conditions provided 
compound 4 in high yield (90 %, two steps). Last, coupling of 1 and 4 in the presence of DIPEA 
generated Pro-PTX in moderate yield (36 %). 
Cytotoxicity study: PTX vs Pro-PTX. To evaluate the inactivation strategy, viability assays 
were performed in three cell lines: non-small cell lung carcinoma A549 cells (cell model of 
human cancer clinically treated with PTX),4,5 human glioblastoma U87 cells (model of 
aggressive brain cancer)49 and human brain vascular pericytes (HBVP, non-cancerous cells that 
are critical components of the blood brain barrier49 and similar to those found in peripheral 
nerves). Cells were treated with PTX and Pro-PTX at a range of concentrations (up to 10 μM) 
and viability measurements carried out after 5 d of treatment. Results were normalized to the 
untreated cell control (1% DMSO) and half maximal effective concentration (EC50) values 
calculated from the generated dose-response curves (see Figure 1). As expected, PTX treatment 
induced a very potent cytotoxic effect against the two cancer cell lines, with EC50 values in the 
range of 2 to 3 nM. In contrast, Pro-PTX did not show activity at most concentrations tested in 
these cell lines, with reduced cell viability only seen at doses ≥1 μM and exhibiting an EC50 
value of 1.75 μM for A549 and 0.54 μM for U87 cells (Figure 1a,b). This vast drop of anticancer 
activity (200 to 700-fold lower than PTX) highlights the essential role of the C2’-OH of PTX for 
binding its target (lumenal side of microtubules)4,5 and the stability of the masking group to 
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enzymatic cleavage and nucleophilic attacks by intracellular biomolecules. As expected, PTX 
and Pro-PTX displayed much lower cytotoxicity in low-proliferating HBVP (Figure 1c). Under 
treatment with PTX, cell proliferation was reduced to 75 % at concentrations ≥1 µM, with an 
EC50 value of 0.047 µM. The antiproliferative effect of Pro-PTX in HBVP was negligible at 
most concentrations (EC50 = 4.4 µM), which is in agreement with an increased safety profile 
relative to its parent drug.   
 
 
Figure 1. Nine-point semilog dose-response curves and calculated EC50 values for (a) A549 cells, (b) U87 
cells and (c) HBVP after 5 d treatment with PTX and Pro-PTX at concentrations ranging from 0.001 to 10 
μM. Error bars: ± SEM from n=3. 
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Prodrug-into-drug conversion studies. Next, the sensitivity of the prodrug to Pd under 
biologically relevant conditions was tested by incubating Pro-PTX at 37 °C in PBS (pH= 7.4, 
isotonicity) with or without a polymer-supported Pd catalyst, 30 µm Pd-devices41 (which can be 
easily filtered off to facilitate the analysis of the reaction mixture). Reactions were monitored by 
MS. While the prodrug remained intact in the absence of Pd (Figure 2a), reaction analysis 
showed the complete disappearance of the prodrug after 10 h incubation with Pd-devices and the 
formation of major mass peaks corresponding to PTX (Figure 2b). The observation of the 
[M2+H]+ peak in the mass spectrum, which corresponds to the amino derivative 5 (highly-
ionizable pre-immolation intermediate), is in agreement with the proposed prodrug activation 
mechanism. 
 
Figure 2. Pd-mediated conversion of Pro-PTX into PTX under biologically relevant conditions. (a) MS 
spectrum of Pro-PTX (100 μM) after 10 h incubation in PBS at 37 °C. (b) MS spectrum of Pro-PTX 
(100 μM) after 10 h incubation with Pd-devices (2 mg/mL) in PBS at 37 °C. 
 
Biodegradable solid supports for Pd catalysts. Bidimensional Pd nanostructures —also called 
Pd nanosheets— have been reported to display good biocompatibility in culture and in vivo50 
and, more recently, shown to catalyze bioorthogonal reactions when they are properly protected 
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structures could be precisely injected at desired anatomical sites (e.g. inside small tumor lesions) 
and, in time, be eliminated from the organism by the renally and/or the hepatobiliary routes;51 
features that are optimal for short-lived therapeutic applications. However, such small 
dimensions also make them capable to permeate through most biological barriers, which would 
defeat the purpose of catalyzing bioorthogonal reactions exclusively at the point of implantation.  
Hydrogels are insoluble porous networks with high water content (up to 95%) that have been 
extensively used as drug reservoirs in controlled release systems.52 However, the potential use of 
physical hydrogels as biocompatible scaffolds for bioorthogonal catalysts has never been tested 
before. Amongst the broad variety of gelling agents available, the FDA-approved natural 
polysaccharides agarose and alginate are especially attractive for medical and pharmaceutical 
applications because of their biodegradable and non-thrombogenic nature.53,54 Driven by the idea 
of creating implantable catalytic devices capable of uncaging Pro-PTX and feature the potential 
to gradually biodegrade over time, we decided to investigate the use of agarose and alginate-
based hydrogels as scaffolds for the immobilization of Pd nanosheets. 
Pd nanosheets were prepared using a new method (adapted from previous works55,56,30) 
consisting of treating an aqueous solution of Na2PdCl4, polyvinyl pyrrolidone and KBr to a CO 
atmosphere in a high-pressure reactor (6 bar) at 80 °C for 40 min (see full protocol in the 
Experimental Section). The employ of low toxicity reagents was addressed to increase the 
biocompatibility of the metallic nanostructures, whereas CO was used as a reductant and capping 
agent to control the shape and size of the nanoparticles.55,56 TEM analysis showed the planar and 
homogeneous shape of the resulting structures (Figure 3a,b), which displayed an average width 
and thickness of 12 ± 2.2 nm and 1.4 ± 0.1 nm, respectively, making them a priori good 
candidates to become trapped in polymeric fibrillar networks. Their planar morphology (which 
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corresponds to less than 9 atomic layers) further agrees with the capacity of the Pd nanosheets 
to absorb in the near infrared range (Figure 3c).50  
A fluorogenic test was first used to determine the catalyst compatibility with physiological 
conditions. Reaction was performed by incubation in PBS at 37 °C with the Pd-labile off/on 
probe O-propargyl-resorufin (Pro-Res)30 at a range of concentrations of Pd nanosheets (5 to 40 
µg/mL in Pd). Changes in fluorescence intensity were measured at 24 h with a 
spectrophotometer (Ex/Em: 540/590 nm) and conversion rates calculated using a standard curve 
of resorufin. Analysis revealed dose-dependent fluorescence increases, with conversion rates 
ranging from 46 to 94% (Fig S3, Supp. Inf.). To determine the fraction of Pd atoms that leaches 
from the Pd nanosheets under the reaction conditions, 20 and 40 µg/mL of Pd nanosheets were 
incubated in PBS at 37 ℃ during 24 h. The mixture was filtered off using StageTips to eliminate 
the solid nanostructures and the quantity of soluble Pd in the filtered solution determined by ICP-
OES. Analysis detected 8.337 (±3.049) and 16.675 ng/mL (±6.090) of Pd in the samples, 
respectively, indicating that just a very small fraction of Pd (approx. 0.042 %) leaches from the 
freestanding Pd nanosheets over this period. Next, to test the inherent cytotoxicity of the 
nanodevices,57 A549 cells were treated with Pd nanosheets for 3 d at the previously tested range 
of concentrations. Cell viability results showed no signs of toxicity at 5 µg/mL of Pd nanosheets 
and good cell tolerability at 10 µg/mL (Fig S4, Supp. Inf.). Last, a prodrug activation study was 
performed to corroborate the capacity of the nanodevices to dealkylate Pro-PTX. The reaction 
was performed as described above but using Pd nanosheets instead of Pd-functionalized 
microdevices. The Pd nanodevices were filtered off using StageTips before analyzing the 
samples by LCMS. Analysis showed the time-dependent disappearance of the prodrug and the 
formation of the peaks corresponding to PTX and the highly-ionizable amino derivative 5 (Fig 
S5, Supp. Inf.). 
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Figure 3. (a,b) TEM images of freestanding Pd nanosheets at two magnifications. (c) UV-Vis absorption 
spectrum of Pd nanosheets. 
 
Once the catalytic activity and the biocompatible dose range of the Pd nanosheets were 
confirmed, the use of hydrogels to immobilize these functional nanodevices was investigated. 
Two biopolymers, agarose and alginate, were tested to take advantage of their different gelling 
properties and to assess the scope of the capture strategy. Hydrogel formation in the presence of 
catalysts was first studied by dissolving agarose in warm biological-grade water at a range of 
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concentrations, followed by mixing with a pre-warmed suspension of Pd nanosheets. 60 µL of 
the mixture were then transferred to tissue culture inserts (0.4 to 8 μm pore) and allowed to cool 
down to room temperature to generate dark-colored hydrogel disks (Pd Agarose) ready to be 
tested in cell culture (Figure 4a). Optimal catalyst capture was obtained using 5 mg/mL of 




Figure 4. (a) Snapshots of the preparation of Pd Agarose and Pd Alginate catalytic hydrogels. (b) 
Representative SEM images of agarose hydrogel (secondary electron detector) and Pd Agarose 
(backscatter electron detector). Bright points observed in the Pd Agarose image indicate the presence of 
metallic Pd. 
Next, the uncaging capabilities of the hydrogel-entrapped catalysts from the tissue culture 
inserts were evaluated by incubation with the off/on probe Pro-Res at physiological conditions. 
Notably, treatment of the probe with Pd Agarose (inserts of 1-8 μm pore size) resulted in an 
increase in fluorescence intensity equivalent to that obtained by freestanding Pd nanosheets at 
the same concentration (Figure 5a). In agreement with the preservation of the catalytic activity, 
analysis of the hydrogel by SEM shows the apparent capture and homogeneous distribution of 
the metallic Pd onto the biopolymer fibers (Figure 4b). This indicates that gelification in the 
presence of a suspension of Pd nanosheets favors their trapping and distribution throughout the 
 13
fibrillar network with little agglomeration,58,59 thus increasing the catalytic exposition area while 
minimizing the escape of the metal. The presence of Pd was further corroborated by Energy 
Dispersive X-ray (Fig S6, Supp. Inf.). 
 
 
Figure 5. (a,b) Conversion of Pro-Res (100 µM) into resorufin by (a) Pd Agarose (40 µg/mL of Pd 
nanosheets placed in 0.4-8 µm pore size inserts) or (b) Pd Alginate (5 to 20 µg/mL of Pd nanosheets) 
after incubation in DMEM culture media (600 µL or 500 µL, respectively) for 16 h at 37 °C in a tissue 
culture incubator. Pro-Res (100 µM) with or without Pd nanosheets were used as negative and positive 
controls, respectively. Fluorescence signal was measured at λex/em 540 / 590 nm. Error bars: ± SD from n 
= 3. (c,d) A549 cell viability study after treatment with (a) Pd Agarose and (b) Pd Alginate hydrogels at 
different concentrations. Pd nanosheets were included as control. Cell viability was measured at day 3. 
Error bars: ± SD from n = 3. 
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Next, because of the capacity of alginate to spontaneously form hydrogels in Ca2+ solutions 
and inspired by previous work from Fortin and coworkers60 on the “injection & capture” strategy 
to immobilize radioactive metal nanoparticles in tumors, the entrapment of Pd nanosheets was 
also tested in alginate hydrogels. A suspension of sodium alginate (20 mg/mL) and Pd 
nanosheets (0.3 mg/mL) was first prepared in warm biological-grade water. Then, hydrogels 
were simply made by dropwise addition of the mixture into PBS or culture media supplemented 
with 100 mM CaCl2, to generate spherical dark-colored hydrogels (Figure 4a and Movie S1). As 
before, treatment of the off-on Pd-labile probe Pro-Res with Pd Alginate spheres demonstrated 
the functional operativity of the catalytic hydrogel (Figure 5b). Remarkably, cell vitality studies 
showed that both Pd Agarose and Pd Alginate hydrogels were better tolerated by A549 cells 
than freestanding Pd nanosheets at equivalent metal concentrations (Figure 5c,d). 
Encouraged by the catalytic properties and biocompatibility of the catalyst-loaded hydrogels, 
the capacity of Pro-PTX to enter and be activated by these novel catalytic systems was tested in 
A549 cells by incubation with Pro-PTX in the presence of Pd- or catalyst-free hydrogels. As 
shown in Figure 6, no reduction of cell proliferation was observed after separately treating A549 
cells with either Pro-PTX or the catalytic hydrogels. In contrast, the combination of Pro-PTX 
and Pd Agarose disk / Pd Alginate spheres potently inhibited cancer cell proliferation, resulting 
in an anticancer activity equivalent to the direct treatment with the parent drug PTX. Equivalent 
results were obtained in the U87 cell line (Fig. S7, Suppl. Inf.). This study demonstrates that, 
despite its structural complexity, Pro-PTX is able to efficiently diffuse across the porous 
hydrogel network and react with Pd nanosheets to be converted into PTX, which then diffuses 













Figure 6. Prodrug activation assays with (a) Pd Agarose and (b) Pd Alginate. Experiments: 0.1% 
DMSO (untreated control, light grey); Pd Agarose or Pd Alginate (–ve control, dark grey); 0.75 µM 
Pro-PTX (–ve control, blue); Pd Agarose or Pd Alginate + 0.75 µM Pro-PTX (activation assay, pink); 
0.75 µM PTX (+ve control, black). Cell viability was measured at day 3. Error bars: ± SEM, n = 3. 
 16
 
Figure 7. Immunofluorescence study. Experiments: (a) Pd Alginate; (b) 0.75 µM Pro-PTX + Alginate 
(no Pd); (c) Pd Alginate + 0.75 µM Pro-PTX (prodrug activation experiment); (d) 0.75 µM PTX. 48 h 
after treatment, cells were fixed and stained with anti-α-tubulin IgG, TRITC-Phalloidin, and DAPI. Left 
panels: α-tubulin stain (green). Right panels: nuclei (cyan) and phalloidin (red). Scale bar= 20 µm. 
 
Last, to corroborate that the mechanism of cell death mediated by the Pro-PTX / Pd hydrogel 
combination was analogous to that mediated by PTX, immunofluorescence studies were 
performed to image microtubule stabilisation.4,5 Cells were fixed after 2 d treatment and 
incubated with an anti-α-tubulin IgG, cell nuclei DAPI stain and TRITC-Phalloidin, and imaged 
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by confocal microscopy (Olympus FV1000). As observed in Figure 7 (see additional control 
experiments in Fig S8, Supp. Inf.), whereas controls showed the tubulin signal (green channel) 
spread throughout the cytoplasm (panels a,b), microtubule accumulation was patently visible 
after PTX treatment (panel d). Importantly, microtubule stabilization was equally evident in cells 
treated with the Pro-PTX / Pd hydrogel combination (panel c), thereby proving that the 
anticancer effect mediated by that combination is a result of the in situ formation of PTX. 
Conclusions 
In the exploration of new ways to improve the safety and efficacy of one of the most important 
anticancer drugs in clinical use, a new prodrug of PTX has been developed. This inactive drug 
precursor features excellent stability in cancer cell culture and high sensitivity to metallic Pd, 
thus enabling selective drug release in the presence of Pd catalysts. The biscarbamate chemical 
mask used to block the 2’-OH position of PTX provides optimal protection for aliphatic alcohols 
and metal sensitivity, representing a novel and useful addition to the current toolbox of 
bioorthogonal uncaging strategies. Moreover, a biocompatible catalytic system based on the 
immobilization of Pd catalysts in physical hydrogels has been developed for the first time. 
Entrapment of Pd nanosheets in agarose and alginate hydrogels exhibited equivalent catalytic 
properties than the free catalysts, and displayed the capacity to convert the inactive prodrug Pro-
PTX into PTX in cancer cell culture. By capturing transition metal catalysts within an inherently 
biodegradable scaffold, this investigation provides a strategy to temporary elicit localized 
biorthogonal uncaging of chemotherapeutics. As exemplified with alginate, the in situ gelling 
strategy in which a liquid suspension containing catalytic nanodevices solidifies in contact with 
environs rich in bivalent cations could offer a minimally invasive solution to locally administer 
and immobilize the catalyst at the disease site. Subsequent studies will focus on progressing 
these innovations into preclinical animal models. 
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Experimental section 
General Methods. Chemicals and solvents were purchased from Fisher Scientific, Sigma-
Aldrich, VWR International Ltd or TCI UK Ltd. PTX was purchased from Fluorochem UK. 
NMR spectra were recorded at ambient temperature on a 500 MHz Bruker Avance III 
spectrometer. Chemical shifts are reported in parts per million (ppm) relative to the solvent peak. 
Rf values were determined on Merck TLC Silica gel 60 F254 plates under a 254 nm UV source. 
Purifications were carried out by flash column chromatography using commercially available 
silica gel (220-440 mesh, Sigma-Aldrich) or via semipreparative TLC chromatography on Merck 
TLC Silica gel 60 F254 plates. High Resolution Mass Spectrometry was measured in a Bruker 
MicrOTOF II. The purity of PTX and Pro-PTX was >95% for cell studies, as measured by 
HPLC using an Agilent 1200 system. HPLC method: eluent A: water and formic acid (0.1 %); 
eluent B: methanol and formic acid (0.1 %); A/B = 95:5 to 5:95 in 4 min, isocratic 2 min (flow = 
1 mL / min). Prodrug-into-drug conversion experiments were conducted in a LCMS (Agilent 
1200) using a micrOTOF II detector. Method A: eluent A: water and formic acid (0.1 %); eluent 
B: acetonitrile and formic acid (0.1 %); A/B = 95:5 isocratic 0.5 min, 95:5 to 0:100 in 4.5 min, 
isocratic 2 min, 0:100 to 95:5 in 0.5 min, and isocratic 2.5 min (flow = 0.2 mL / min). Method B: 
A/B = 80:20 to 0:100 in 10 min, isocratic 3 min, 0:100 to 80:20 in 5 min (flow = 0.3 mL / min). 
Stock solutions (100 mM) were prepared in DMSO. SEM images were performed using a FEI 
Quanta 400 ESEM equipped with an EDX analytical system. A portion of hydrogel was 
supercriticaly dried and coated with a fine carbon layer. Afterwards, the samples were examined 
by SEM using secondary and backscatter electron detectors. ICP-OES measurement were carried 
out in a Varian 715 ICP optical emission spectrometer. 
Synthesis of 2’-(4-nitrophenoxycarbonyl)paclitaxel (1). 2’-(4-
nitrophenoxycarbonyl)paclitaxel, 1, was synthesised according to literature procedure.11  
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Synthesis of N-(propargyloxycarbonyl)-N,N’-dimethylethylenediamine (4). Tert-butyl 
methyl[2-(methylamino)ethyl]carbamate, 2 (284 mg, 1.5 mmol) and pyridine (275 µL, 3.4 
mmol) were dissolved in a mix of H2O:1,4-dioxane (3:6, 9 mL). A solution of propargyl 
chloroformate (221 µL, 2.3 mmol) in 1,4-dioxane (1 mL) was then added dropwise to the 
mixture at room temperature and the reaction stirred overnight. Subsequently, solvents were 
removed by rotary evaporation, the crude dissolved in CH2Cl2 (20 mL), and the mixture washed 
with an aqueous solution of 1N HCl (2 x 15 mL) and water (2 x 15 mL). The organic phase was 
dried over anhydrous MgSO4 and concentrated by rotary evaporation. The crude residue was 
purified by flash chromatography with 2.5% MeOH in CH2Cl2 to give compound 3 as a pale oil. 
Rf = 0.48 (5% MeOH in CH2Cl2). Without further characterization, compound 3 was then 
dissolved in a 9:1 (v/v) mixture of TFA/water (5 mL) and the mixture stirred at room 
temperature for 2 h. Solvents were removed by rotary evaporation and the addition of cold 
diethyl ether (10 mL) afforded pure compound 4 as a yellow solid (90% yield, two steps). Rf = 
0.15 (5% MeOH in CH2Cl2). 1H NMR (500 MHz, DMSO-d6) δ 8.48 (s, 1H), 4.68 (s, 2H), 3.55 
(s, 1H), 3.50 (t, J = 6.0 Hz, 2H), 3.08 (t, J = 6.0 Hz, 2H), 2.87 (s, 3H), 2.58 (s, 3H). 13C NMR 
(126 MHz, DMSO-d6) δ 155.8 (C), 79.5 (C), 78.0 (CH), 53.4 (CH2), 46.5 (CH2), 45.5 (CH2), 
34.4 (CH3), 33.2 (CH3). HRMS (ESI) m/z [M + H]+ calcd for C8H15N2O2, 171.11280; found, 
171.11360. 
Synthesis of Pro-PTX. Compound 1 (14 mg, 14 µmol) was dissolved in dry DMF (1 mL) under 
N2 atmosphere and cooled down to 0°C. Compound 4 (7 mg, 42 µmol) and DIPEA (12 µL, 70 
µmol) were dissolved in dry DMF (0.5 mL) and added dropwise to the solution and the mixture 
allowed to reach room temperature and stirred overnight. The solvent was removed by rotary 
evaporation and the crude purified by via semipreparative TLC chromatography (2.5% MeOH in 
CH2Cl2) to yield a white solid (36% yield). Rf = 0.40 (5% MeOH in CH2Cl2). 1H NMR (500 
 20
MHz, DMSO-d6) δ 9.17 (d, J = 8.9 Hz, 1H), 7.98 – 7.94 (m, 2H), 7.87 – 7.81 (m, 2H), 7.73 (t, J 
= 7.5 Hz, 1H), 7.65 (t, J = 7.5 Hz, 2H), 7.59 – 7.53 (m, 1H), 7.49 (t, J = 7.3 Hz, 2H), 7.47 – 7.43 
(m, 4H), 7.19 – 7.17 (m, 1H), 6.29 (s, 1H), 5.87 – 5.81 (m, 1H), 5.66 – 5.54 (m, 1H), 5.41 (d, J = 
7.2 Hz, 1H), 5.30 – 5.12 (m, 1H), 4.88 (dd, J = 14.5, 8.5 Hz, 2H), 4.62 – 4.52 (m, 2H), 4.13 – 
4.08 (m, 1H), 4.03 – 3.97 (m, 2H), 3.58 (d, J = 7.1 Hz, 1H), 3.46 (d, J = 6.6 Hz, 1H), 3.40 (s, 
1H), 2.88 (s, 1H), 2.85 (s, 1H), 2.81 (s, 1H), 2.77 (d, J = 6.9 Hz, 1H), 2.72 (d, J = 0.6 Hz, 2H), 
2.35 – 2.20 (m, 4H), 2.10 (d, J = 1.5 Hz, 3H), 1.81 – 1.78 (m, 4H), 1.62 (t, J = 13.0 Hz, 2H), 1.49 
(s, 4H), 1.34 (s, 1H), 1.22 (s, 2H), 1.01 (d, J = 7.4 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δ 
202.9, 170.1, 169.2, 167.0, 165.7, 155.1, 140.9, 140.4, 137.8, 134.7, 134.0, 131.9, 130.5, 130.1, 
129.2, 128.8, 128.6, 128.2, 127.8, 126.8, 116.6, 84.1, 80.7, 79.6, 77.6, 77.2, 76.5, 75.8, 75.2, 
75.0, 71.1, 70.9, 66.1, 65.5, 60.2, 57.8, 55.4, 54.5, 52.9, 46.6, 43.4, 37.0, 34.9, 33.7, 32.9, 26.8, 
23.0, 21.9, 21.2, 21.1, 20.8, 19.3, 15.6, 14.6, 14.4, 10.2. HRMS (ESI) m/z [M + H]+ calcd for 
C56H64N3O17, 1050.42302; found, 1050.42120. Purity as measured by HPLC was >99%. 
Synthesis of O-propargyl-resorufin. Pro-Res was synthesised according to literature 
procedure.30 
Cell viability study: PTX vs Pro-PTX. A549 cells (a kind gift from Dr Wilkinson) and U87 
cells (a kind gift from Dr Gammoh) were seeded in a 96-well plate format (at 1,500 and 2,000 
cells/well, respectively) in DMEM supplemented with 10 % of FBS and L-glutamine (2 mM) 
and incubated in a tissue culture incubator at 37 °C and 5% CO2 for 24 h before treatment. 
HBVP (kind gift from Dr Caporali) were seeded at 10,000 cells (to reach confluency) in pericyte 
media (ScienCell Research Laboratories, Inc., USA) on gelatin (0.1%) / fibronectin (10μg/ml) 
pre-coated dishes. Each well was then replaced with fresh media, containing compounds PTX 
and Pro-PTX (0.001-10 µM). Untreated cells were incubated with DMSO (0.1 % v/v). After 3 d 
of incubation, PrestoBlueTM cell viability reagent (10 % v/v) was added to each well and the 
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plate incubated for 90 min. Fluorescence emission was detected using a PerkinElmer EnVision 
2101 multilabel reader (Ex / Em: 540 / 590 nm). All conditions were normalized to the untreated 
cells (100 %) and curves fitted using GraphPad Prism using a sigmoidal variable slope curve. 
Experiments were performed in triplicates. 
Prodrug-into-drug conversion studies. Pro-PTX (100 μM) was dissolved in PBS (1 mL) with 
2 mg of Pd devices (Pd-resins diameter size 30 µm, made as previously reported41) and 
incubated at 37 °C in a Thermomixer at 1,200 rpm during 10 h. Reaction crudes were centrifuged 
(13,000 rpm, 5 min) to sediment the Pd-devices and supernatants were analyzed by LCMS/MS 
(Agilent 1200) using a micrOTOF II detector. PTX (100 μM) was dissolved in PBS (1 mL) for 
10 h and analyzed as a positive control. 
Preparation of Pd nanosheets. The synthesis of Pd nanosheets was based in previous protocols 
reported,54,55,30 but with modifications to avoid the use of toxic quaternary ammonium salts. The 
palladium growth solution was prepared by mixing 11 mg of Na2PdCl4, 30 mg of polyvinyl 
pyrrolidone (MW = 55,000) and 130 mg of KBr in Milli-Q water (400 µL). The resulting 
homogeneous red solution was mixed with 4 mL of DMF. The Pd nanosheet precursor solution 
was introduced in a high-pressure stainless-steel Teflon lined reactor. CO gas was introduced in 
the high-pressure reactor to reduce the Pd precursor and control the anisotropic shape of the Pd 
nanostructures.54 The pressure inside the reactor was maintained at 6 bar and the reactor was 
introduced in a heated water bath (80 ºC for 40 min). The solution was gently stirred with a 
magnetic flea located at the high-pressure reactor. A dark blue colloid was obtained after the CO 
treatment. Pd nanosheets were collected by centrifugation (10,000 rpm, 10 min) by mixing the 
dark blue colloid and acetone in a volume ratio of 1 to 3. Finally, Pd nanosheets were dispersed 
in Milli-Q water and kept at 5º C for further use. The Pd concentration was determined by MP-
AES (Microwave Plasma-Atomic Emission Spectrometer 4100 Agilent Technologies) and the 
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optical properties were analysed by UV-VIS spectrophotometry (Jasco V-670). TEM (Tecnai 
FEI T20) used to study the Pd nanosheets morphology by operating at an acceleration voltage of 
200 kV with a LaB6 electron source fitted with a SuperTwin® objective lens allowing a point-to-
point resolution of 2.4 Å. TEM images showed that the Pd nanosheets tend to stack during the 
drying process of the TEM grid preparation. This effect enabled to observe the ultra-thin sheet 
like morphology and eased their direct thickness measurement. Leaching of Pd nanosheets after 
incubation for 24 h in PBS was studied by ICP-OES using a Varian 715 ICP optical emission 
spectrometer. 
Preparation of Pd Agarose. Pd nanosheets were embedded in agarose hydrogels (5 mg/mL) 
with a Pd concentration of 0.4 mg/mL. Agarose powder (UltraPureTM Agarose, Thermo Fisher 
Sci.) was weighted in an Eppendorf tube and sterilized by UV radiation. MilliQ water was 
filtered through a 0.22 µm mesh filter and was added to the agarose powder. The mixture was 
shacked and warmed at 80 ºC for 5 min to achieve a complete solution. The solution obtained 
was added on a pre-warmed Pd nanosheets suspension and was homogenized by pipetting up 
and down several times. Immediately after, 60 µL of the suspension were pipetted into tissue 
culture inserts (Corning Transwell®), placed in a 24 well-plate and allowed to cool at room 
temperature for 1 h. Afterwards, the 24 well-plate was sterilized under UV radiation for 30 min 
before characterization and use in cell assays.  
Preparation of Pd Alginate. Pd nanosheets were embedded in alginate hydrogels with a Pd 
nanosheets concentration of 0.3 mg/mL. Sodium alginate powder (Sigma Aldrich, W201502) 
was dissolved in sterile water and Pd nanosheets were added and vortexed until 
homogenisation. The mixture was sterilised under UV for 15 min. The suspension was added 
dropwise into standard cell culture medium (DMEM, 10% FBS, 2 mM L-Glutamine) 
supplemented with 100 mM CaCl2 dihydrate in 24 well-plates to form dark alginate beads. Beads 
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were washed twice with DMEM and transferred to the experiment wells (3 beads / 500 μL, final 
concentration of Pd of approx. 20 µg/mL). 
Cell toxicity studies: Pd nanosheets vs Pd hydrogels. A549 cells were cultured in DMEM 
supplemented with 10 % of FBS and L-glutamine (2 mM) and incubated in a tissue culture 
incubator at 37 °C and 5% CO2. A549 cells were seeded in a 24-well plate format (at 9,000 cells 
/ well) and incubated for 24 h before treatment. For Pd nanosheets, each well was replaced with 
a suspension of Pd nanosheets in fresh culture media at 5, 10, 20 and 40 µg/mL of metal (600 
µL final volume). For Pd Agarose, each well was replaced with fresh media (540 µL). Agarose 
hydrogels containing Pd nanosheets were prepared following the procedure previously 
described and placed in cell culture inserts with 1 µm pore size (60 µL, 5-40 µg/mL of metal 
concentration). For Pd Alginate, each well was replaced with fresh media (500 µL). Pd 
Alginate hydrogels were prepared as described above and added at 1-3 beads/well (5-20 µg/mL 
of metal concentration). After 3 d of incubation, PrestoBlueTM cell viability reagent (10 % v/v) 
was added to each well and the plate incubated for 180 min. Fluorescence emission was detected 
using a PerkinElmer EnVision 2101 multilabel reader (Ex / Em: 540 / 590 nm). Experiments 
were performed in triplicates. 
Fluorogenic assays: Pd nanosheets vs Pd hydrogels. Pro-Res (100 μM) was dissolved in 
DMEM culture media (in 540 µL for Pd Agarose hydrogels or in 500 µL for Pd Alginate 
hydrogels) in a 24-well plate format. For Pd Agarose, hydrogels containing Pd nanosheets at 40 
µg/mL (60 µL) were prepared following the procedure above described and placed in cell culture 
inserts (0.4-8 µm pore size). For Pd Alginate, hydrogels containing Pd nanosheets at approx. 5-
20 µg/mL (1 to 3 beads/well) were prepared following the procedure previously described. Pd 
nanosheets (20 and 40 µg/mL) were used as control. Samples were incubated at 37°C in a tissue 
culture incubator. Pd nanosheets were removed by centrifugation (13,000 rpm, 30 min). 
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Fluorescence intensity of 100 µL of supernatants transferred to a 96-well plate format was 
measured in a PerkinElmer EnVision 2101 multilabel reader (Ex / Em: 540 nm / 590 nm). 
Samples were repeated in triplicate. The percentage of conversion was calculated based on the 
fluorescence signal of positive control Resorufin at 100 µM. 
Prodrug activation assays with Pd hydrogels. A549 were seeded in a 24-well plate format (at 
9,000 cells / well) and incubated for 24 h before treatment. Each well was replaced with fresh 
culture media containing Pro-PTX or PTX (0.75 µM). Untreated cells were incubated with 
DMSO (0.1 % v/v). Pd Agarose and Alginate hydrogels (40 µg/mL of metal and 20 µg/mL, 
respectively) were prepared following the procedure previously described. Pd Agarose 
hydrogels were placed in cell culture inserts with 1 µm pore size and Pd Alginate hydrogels 
added at 3 beads/well. After 3 d of incubation, cell viability was determined as described above. 
Experiments were performed in triplicates. 
Immunofluorescence studies. A549 cells were seeded on 10 mm poly(L-lysine) precoated 
coverslips in 24 well plates (5,000 cells/well). After 24 h, cells were incubated in the presence or 
in the absence of alginate gels and/or Pro-PTX / PTX (0.75 µM) in 500 μL of DMEM in 
triplicates. After 48 h, cells were fixed with paraformaldehyde (4% v/v) for 10 min and washed 3 
times with PBS every 5 min. Cells were permeabilized for 15 min with 0.3% Tween in PBS and 
washed 3 times with PBS every 5 min. Coverslips were incubated in blocking buffer (1x PBS, 
5% Goat serum, 0.3% Triton X-100) for 60 min. Anti-α-tubulin Rabbit mAb (Cell Signaling 
Technology) was incubated overnight at 4°C in antibody dilution buffer (1x PBS, 1% BSA, 0.3% 
Triton X-100) at a dilution of 1:25. After washing 3 times with PBS, coverslips were incubated 
for 30 min in antibody dilution buffer (1x PBS, 1% BSA, 0.3% Triton X-100) with Alexa Fluor 
488 Goat anti-Rabbit IgG (H+L) Secondary Antibody (Invitrogen) at a dilution of 1:400. 
Coverslips were washed three times with PBS and mounted on a slide with a 1:1 mixture of 
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VECTASHIELD® Hardset™ Antifade Mounting Medium with Phalloidin: VECTASHIELD® 
Antifade Mounting Medium with DAPI. Cells were imaged using a scanning confocal inverted 
microscope Olympus FluoView FV1000 (Olympus, Tokyo, Japan) with a 60x oil immersion 
objective. The images were acquired FV10-ASW program in a sequential mode using software 
pre-configured settings for Alexa Fluor 488 and TIRTC and analysed with Image-J software to 
obtain maximal projections. 
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